Brief: Mira Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2
23/08/2024 23:05
Aug 23 (Reuters) - Mira Pharmaceuticals Inc MIRA.O :
* MIRA PHARMACEUTICALS- ACHIEVES 100% REVERSAL OF
NEUROPATHIC PAIN
WITH ORAL KETAMIR-2 IN BREAKTHROUGH STUDY
Source text for Eikon: ID:n0001493152-24-033718
Further company coverage: MIRA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing